Insider Selling: Crispr Therapeutics AG (CRSP) Insider Sells $15,225.00 in Stock

Crispr Therapeutics AG (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 700 shares of the business’s stock in a transaction dated Friday, December 28th. The shares were sold at an average price of $21.75, for a total value of $15,225.00. Following the sale, the insider now owns 115,904 shares of the company’s stock, valued at $2,520,912. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Tyler Dylan-Hyde also recently made the following trade(s):

  • On Tuesday, January 2nd, Tyler Dylan-Hyde sold 38,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $21.64, for a total value of $822,320.00.
  • On Friday, December 29th, Tyler Dylan-Hyde sold 31,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $22.72, for a total value of $704,320.00.
  • On Friday, December 22nd, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.55, for a total value of $308,250.00.
  • On Friday, December 15th, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.90, for a total value of $283,500.00.

Crispr Therapeutics AG (NASDAQ:CRSP) traded up $0.39 during midday trading on Friday, reaching $23.91. The company had a trading volume of 708,400 shares, compared to its average volume of 998,700. Crispr Therapeutics AG has a one year low of $11.63 and a one year high of $27.39. The stock has a market cap of $1,100.00 and a PE ratio of -74.72.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $3.61 million. During the same period in the prior year, the firm posted ($2.77) earnings per share. The firm’s revenue for the quarter was up 54.2% on a year-over-year basis. equities analysts predict that Crispr Therapeutics AG will post -2.46 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of CRSP. Allianz Asset Management GmbH purchased a new position in Crispr Therapeutics in the 3rd quarter worth approximately $2,384,000. Granahan Investment Management Inc. MA lifted its holdings in Crispr Therapeutics by 51.7% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock worth $4,713,000 after purchasing an additional 89,839 shares in the last quarter. Adams Street Partners LLC purchased a new position in Crispr Therapeutics in the 3rd quarter worth approximately $1,019,000. Hershey Trust Co. purchased a new position in Crispr Therapeutics in the 3rd quarter worth approximately $768,000. Finally, JPMorgan Chase & Co. purchased a new position in Crispr Therapeutics in the 3rd quarter worth approximately $536,000. 24.52% of the stock is currently owned by institutional investors.

A number of research analysts recently issued reports on CRSP shares. Barclays reiterated a “buy” rating and set a $29.00 price objective on shares of Crispr Therapeutics in a research note on Friday, September 8th. BidaskClub upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Oppenheimer reiterated a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a research note on Sunday, December 10th. Finally, SunTrust Banks reiterated a “hold” rating and set a $16.00 price objective on shares of Crispr Therapeutics in a research note on Friday, November 10th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $22.38.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Crispr Therapeutics AG (CRSP) Insider Sells $15,225.00 in Stock” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/05/insider-selling-crispr-therapeutics-ag-crsp-insider-sells-15225-00-in-stock.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply